Regeneron hits 52-week high after 'standout' Q3
FROM THE WIRE · SEEKINGALPHA.COM
Dzmitry Dzemidovich Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/symbol/REGN]) hit a new 52-week high on Friday after the pharma giant delivered what Seeking Alpha Investing Group Leader ONeil Trader [https://seekingalpha.com/author/oneil-trader] called a “standout…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong quarterly sales growth driven by Dupixent is relevant for the Regeneron stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Regeneron hit a new 52-week high on Friday.
- 02Q3 net sales rose 36% year-over-year to $5.1 billion.
- 03Growth was driven mainly by Dupixent, marketed with Sanofi.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Regeneron Pharmaceuticals, Inc.927.89 USDMarket closedtoday +13.33%Positive Sanofi44.34 USDMarket closedtoday +2.81%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets